Efficacy of Duloxetine for Chronic postsurgical Pain after Total Hip Arthroplasty

Efficacy of Duloxetine for Chronic postsurgical Pain after Total Hip Arthroplasty A randomized controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031210331

Enrollment

100

Registered

2021-09-22

Start date

2021-09-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition Hip Osteoarthritis

Interventions

In the duloxetine group, in addition to the usual treatment, 60 mg of duloxetine is orally administered once a day. The dosage should be started at 20 mg per day 4 weeks before surgery and increased b

D000068736

Duloxetine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have osteoarthritis of hip 2) Aged more than 20 years 3) Persons who have not taken duloxetine or two weeks since last dose 4) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Persons with a history of hypersensitivity to the duloxetine 2) Persons administering monoamine oxidase (MAO) inhibitors 3) Persons administering medicines that have a strong inhibitory effect on CYP1A2 4) Persons with severe liver damage (ALAT or ASAT>100IU/L) , history of liver cirrhosis, or liver transplantation 5) Persons with renal damage (eGFR 7) 7) Persons with alcohol or other dependence within 5 years 8) Persons with severe cardiovascular disease 9) Hyponatremia (<135 nmol/L) 10) Persons with uncontrolled hypertension 11) Patients with glaucoma, thyroid disease, or epilepsy 12) Persons who are or may be pregnant 13) Persons with a history of hypersensitivity to the Non-Steroidal Anti-Inflammatory Drugs or aspirin-induced asthma. 14) Persons who are judged by the research-responsible (sharing) doctor to be inappropriate for participation in this research

Design outcomes

Primary

Measure	Time frame
Change in NRS after total hip arthroplasty	—

Secondary

Measure	Time frame
Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire (JHEQ) pain catastrophizing scale (PCS) Merle d'Aubigne-Postel hip score (MDP) Postoperative analgesics (excluding duloxetine) Vitality Index	—

Contacts

Public ContactMasanori Nishi

Showa University Hospital

ds110646@med.showa-u.ac.jp+81-3-3784-8543

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026